[Phosphatases 8. Alkaline phosphatase and its isoenzymes in neoplastic diseases of blood (author's transl)].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Both cytoplasmic and surface-membrane antigens of human spermatozoa were detected by means of monoclonal antibodies (MoAbs) and of the alkaline phosphatase anti-alkaline phosphatase- (APAAP-) technique. Several advantages of this technique for the identification of sperm could be demonstrated. The labeling of cytocentrifuge preparations from 16 ejaculates proved the presence of glycosphingolipids, nuclear and mitochondrial antigens of spermatozoa. However, there were no HLA-molecules and other leukocyte antigens on sperm cells.
Sera containing the rare alkaline phosphatase-immunoglobulin G complex were studied to try to determine the type of interaction involved. Pepsin and papain digestion of immunoglobulin G showed that alkaline phosphatase was attached to the F(ab')2 region of the immunoglobulin molecule and not to the Fc region. Sialic acid did not play a role in this attachment. Attempts to generate the complex in vitro using polyclonal immunoglobulin, and attempts to dissociate the complex is an immune complex in vitro, were both unsuccessful. It is concluded that the complex is an immune complex formed by antibody-antigen reaction in the circulation, and consists of two molecules of monovalent alkaline phosphatase associated with one molecule of divalent immunoglobulin G.
Macromolecular alkaline phosphatase (EC 3.1.3.1) was found in the serum of a patient suffering from myasthenia gravis (adult type II) complicated with thymoma, and was shown by immunoelectrophoresis to be bound to immunoglobulins A and G (IgG). Placental alkaline phosphatase, complexed with either the patient's serum or IgG purified from the patient's serum, remained at the origin on electrophoresis, with significant loss of activity. Intestinal alkaline phosphatase, complexed with either the patient's serum or the patient's IgG, migrated to a position similar to that of the macromolecular alkaline phosphatase in the patient's serum on electrophoresis. About 50% of the placental alkaline phosphatase activity was inhibited with 0.1-0.2 g of the patient's IgG per liter, but 6.93 g of the IgG per liter was required for about 20% inhibition of the intestinal alkaline phosphatase activity. The complex of intestinal alkaline phosphatase with the patient's IgG was fairly heat stable. From these results, we concluded that the macromolecular alkaline phosphatase in the patient's serum consisted of intestinal alkaline phosphatase and IgG that was specific for placental alkaline phosphatase.
Explore the source record for details and available documents.
An intestinal alkaline phosphatase-like (Kasahara) isoenzyme has been isolated from the serum of a patient with lung cancer and compared with foetal intestinal alkaline phosphatase from the serum of a premature infant and with adult intestinal phosphatase isolated from serum in the same way. Although the ligand-binding sites of the three enzymes were indistinguishable, the foetal intestinal and Kasahara isoenzymes differed slightly from the adult isoenzyme in heat stability and markedly in electrophoretic mobility and neuraminidase-sensitivity, while themselves being similar in these respects. Neither the Kasahara isoenzyme nor foetal phosphatase reacted with anti-placental phosphatase monoclonal antibodies. These results suggest that the Kasahara isoenzyme corresponds to the reappearance of foetal intestinal alkaline phosphatase, rather than to modification of the adult intestinal isoenzyme.
We have established tartrate-resistant acid phosphatase (TRAP) and alkaline phosphatase (ALP) double-positive cell lines (CCP-2, CCP-7, CCP-8) from hamster bone marrow. Accumulation of mineral deposits was observed on the dishes when the clones were cultured in McCoy's 5A medium supplemented with 20% fetal calf serum. The materials were dissolved in 0.05 N HCl, and proteins found in the acid extracts were identified by N-terminal amino acid sequencing. The major components were bovine fetuin and prothrombin precursor. In addition, several cell-derived proteins, such as high mobility group 1 protein (HMG1), secretory leukocyte protease inhibitor (SLPI) and EPV20, a 2.0-kDa milk glycoprotein, were identified. HMG1 was detected, by immunostaining, on the cell surface of all the CCP clones. Metabolically labeled cellular sphingomyelin, sialyllactosylceramide, and proteoglycans were also found in the mineral deposits. Reverse transcription/polymerase chain reaction of CCP-2 mRNA revealed that the cells synthesized alkaline phosphatase, bone sialo protein, and osteonectin, but not matrix Gla protein, osteopontin, and type I collagen. CCP-2 cells formed tumors when injected subcutaneously into nude mice. In the tumor tissue, Alizarin-red-positive nodules surrounded by TRAP- and ALP-positive cells were observed, indicating CCP-2 cells can also induce calcification in vivo.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A cDNA clone for human adult intestinal alkaline phosphatase (ALP) [orthophosphoric-monoester phosphohydrolase (alkaline optimum); EC 3.1.3.1] was isolated from a lambda gt11 expression library. The cDNA insert of this clone is 2513 base pairs in length and contains an open reading frame that encodes a 528-amino acid polypeptide. This deduced polypeptide contains the first 40 amino acids of human intestinal ALP, as determined by direct protein sequencing. Intestinal ALP shows 86.5% amino acid identity to placental (type 1) ALP and 56.6% amino acid identity to liver/bone/kidney ALP. In the 3'-untranslated regions, intestinal and placental ALP cDNAs are 73.5% identical (excluding gaps). The evolution of this multigene enzyme family is discussed.
Explore the source record for details and available documents.
1. Alkaline phosphatase (orthophosphoric-monoester phosphohydrolase (alkaline optimum), EC 3.1.3.1) from human intestine was purified with concanavalin A-Sepharose and tyraminyl derivative-Sepharose affinity chromatography. The enzyme obtained with these techniques had a specific activity of approx. 513.2 mumol p-nitrophenylphosphate hydrolyzed per min per mg of protein at pH 10.0. 2. The highly purified enzyme showed one major enzymatically active band and a possible minor enzymatically active band on acrylamide gel and cellogel electrophoresis, and the two fraction types showed identical antigenicity. 3. The highly purified intestinal enzyme was compared with the purified hepatic enzyme: the saccharide content of each showed a marked difference. 4. The interaction of alkaline phosphatase with concanavalin A, a carbohydrate-binding protein, was studied. Concanavalin A showed an organ-specific behavior to alkaline phosphatase isoenzyme, i.e., the effect on the enzyme activity, and the optimum pH of the activity. 5. The concanavalin A and alkaline phosphatase complex showed a protective effect against heat denaturation and inactivation of proteinase digestion. There was no difference in stability between the intestinal enzyme and the hepatic enzyme. 6. Alkaline phosphatase preparations from human intestine and human liver can bind with concanavalin A; these interactions of concanavalin A; these interactions of concanavalin A with the enzyme occurred reversibly when alpha-methyl-D-mannoside was added. 7. The double reciprocal plots of 1/v vs. 1/s at higher concentrations of concanavalin A showed that the mechanism of inhibition was "mixed type". From the results of Dixon plots, the inhibition constant (Ki) was calculated to the 0.025 muM for human intestinal enzyme. 8. The effect of concanavalin A on L-phenylalanine inhibition of the intestinal alkaline phosphatase indicates that concanavalin A does not interfere with L-phenylalanine binding, but its effect on L-homoarginine inhibition of the hepatic enzyme seems to show that concanavalin A interfered with L-homoarginine binding.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
1. Neonatal mice received subcutaneous injections of buffer, thiourea (TU) or propylthiouracil (PTU). 2. The PTU-treated mice were sacrificed on postnatal day 14 (P14) and the TU-treated mice on P28. 3. Brain weights of the TU- and PTU-treated mice were not significantly different from the controls. 4. Acid but not alkaline phosphatase activity in the brainstem decreased after TU and PTU treatment. 5. Myelination as indicated by intensity of luxol fast blue staining was weaker in the drug-treated animals. 6. The level of myelin marker enzyme, 2',3'-cyclic nucleotide 3'-phosphohydrolase, was lower in the brainstem of PTU-treated animals. 7. The results suggest a correlation between acid phosphatase but not alkaline phosphatase activity with myelination in the developing mouse brain.